Related references
Note: Only part of the references are listed.Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
M. Fiegl et al.
ANNALS OF HEMATOLOGY (2014)
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
Agostino Cortelezzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Hematologist/Oncologist Disease-Specific Expertise and Survival: Lessons from Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Tait D. Shanafelt et al.
CANCER (2012)
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
Michael Fiegl et al.
ANNALS OF HEMATOLOGY (2011)
State of the art treatment of chronic lymphocytic leukaemia
Michael Hallek et al.
BLOOD REVIEWS (2011)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Claes Karlsson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Rediscovering alemtuzumab: current and emerging therapeutic roles
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
A. Cortelezzi et al.
LEUKEMIA (2009)
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
A. Osterborg et al.
LEUKEMIA (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
Constantine S. Tam et al.
LEUKEMIA & LYMPHOMA (2007)
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia - A nation-wide retrospective study in Austria
Michael Fiegl et al.
CANCER (2006)
Strategies in the management of alemtuzumab-related side effects
Anders Osterborg et al.
SEMINARS IN ONCOLOGY (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
KR Rai et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
J Lundin et al.
BLOOD (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Share Paper
